<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62116">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957436</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1105</org_study_id>
    <nct_id>NCT01957436</nct_id>
  </id_info>
  <brief_title>A Phase III of ADT +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer.</brief_title>
  <acronym>PEACE1</acronym>
  <official_title>A Prospective Randomised Phase III Study of Androgen Deprivation Therapy With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase III study to compare the clinical benefit of androgen
      deprivation therapy with or without local radiotherapy with or without abiraterone acetate
      and prednisone in patient with metastatic hormone-naïve prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomize in the trial after his consent form has been signed, and
      after all inclusion and non-inclusion criteria have been checked.

      The randomisation will result in the allocation of arm A (ADT), arm B (ADT + Abiraterone),
      arm C(ADT + radiotherapy) or arm D (ADT + Abiraterone + radiotherapy) in a 1:1:1:1 ratio.

      The randomization will be stratified (by minimization) according to:

        -  enrolment center,

        -  performance status (0 vs. 1-2)

        -  disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of
           visceral metastases.

      CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological
      progression) with serum testosterone being at castrated levels (&lt;0.50 ng/mL).

      When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be
      maintained in all patients. Patients from arm B and D will then stop abiraterone (in
      selected cases e.g. slow/asymptomatic progressions, the investigator may consider continuing
      ADT + abirateroneprednisone at CRPC, rather than switching directly to another therapy, for
      patients included in the abiraterone arms, the use of prednisone at this stage is left to
      the investigator decision).

      Investigators will be free to manage patients reaching CRPC at their discretion (using for
      example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc)
      according to local uses and guidelines. Abiraterone may be used in arm A and C if
      abiraterone has become the standard treatment for CRPC when this stage is reached.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5.5 years after the first inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall and progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PSA response rate will be defined by an undetectable serum PSA level at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective correlative study of PSA response/progression</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>will be evaluated by questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next skeletal-related event</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to chemotherapy</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to severe local symptoms</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to severe local symptoms (grade 3 and 4 events) related to tumor progression and/or radiotherapy long term side effets will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicity (with a specific focus on the use of long-term low-dose steroids) will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The radiological progression-free survival</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of radiotherapy protocol on outcome</measure>
    <time_frame>5.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">916</enrollment>
  <condition>Prostate Cancer Adenocarcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>androgen deprivation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>androgen deprivation therapy + abiraterone acetate + prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A + radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B + radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate</intervention_name>
    <description>abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Androgen Deprivation Therapy</intervention_name>
    <description>The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate,

          2. Metastatic disease documented by positive bone scan or CTscan or MRI. For patients
             with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes can
             be included if they have either:

               -  At least one extra-pelvic lymph node ≥ 2 cm or

               -  extra-pelvic lymph node (s) ≥ 1 cm if the patients also have at least one pelvic
                  lymph node ≥ 2 cm

          3. Patients with ECOG ≤ 1 (PS 2 due to bone pain accepted),

          4. Life expectancy ≥ 6 months,

          5. Male aged ≥ 18 years old,

          6. Hemoglobin ≥ 10.0 g/dL,

          7. Platelet count ≥ 100,000/μL,

          8. Serum creatinine &lt; 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min,

          9. Serum potassium &gt; 3.5 mmol/L,

         10. Serum bilirubin ≤ 1.5 x ULN (except documented Gilbert's disease); AST and ALT ≤ 2.5
             x ULN (≤ 5 ULN in case of liver metastases),

         11. Patients might have received a maximum of 3 months of ADT before randomization,

         12. Patients might have received previous radiation therapy directed to bone lesions, as
             far as it is terminated by the time of randomization,

         13. Patients able to take oral medication,

         14. Patients who have received the information sheet and signed the informed consent
             form,

         15. Male patients who are receiving the study treatment and have partners of childbearing
             potential are advised to use a method of birth control with adequate barrier
             protection (condoms) as determined to be acceptable by the study doctor during the
             treatment period and for 4 weeks after the last dose of the study treatment.

         16. Patients must be willing and able to comply with scheduled visits, treatment plan,
             laboratory tests and other study procedures,

         17. Patients with a public or a private health insurance coverage,

        Exclusion Criteria:

          1. Patients with previous local treatment directed to the prostate primary cancer. A
             previous TURP is allowed,

          2. Prior cytotoxic chemotherapy or biological therapy for the treatment of CRPC,

          3. Any chronic medical condition requiring a higher dose of corticosteroid than 5mg
             prednisone/prednisolone twice daily,

          4. Active infection or other medical condition for which corticosteroid use would be
             contraindicated,

          5. Previously treated with ketoconazole for prostate cancer for more than 7 days,

          6. Prior systemic treatment with an azole drug within 4 weeks of randomization,

          7. Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg),

          8. Patients with a history of hypertension except if blood pressure is controlled by
             anti-hypertensive treatment,

          9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's
             disease),

         10. History of pituitary or adrenal dysfunction,

         11. Small cell carcinoma of the prostate,

         12. Clinically known significant heart disease (myocardial infarction, arterial
             thrombotic events in the past 6 months, severe or unstable angina,NYHA Class II-IV
             heart disease or cardiac EF &lt; 50% at baseline,

         13. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,

         14. Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of
             recurrence within 24 months,

         15. Known allergies, hypersensitivity or intolerance to the study drugs or excipients,

         16. Administration of an investigational therapeutic within 30 days of M1 D1,

         17. Patients already included in another therapeutic trial involving an experimental
             drug,

         18. Patients with significantly altered mental status prohibiting the understanding of
             the study or with psychological, familial, sociological or geographical condition
             potentially hampering participation,

         19. Individual deprived of liberty or placed under the authority of a tutor.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilhem ROUBAUD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié - Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor LATORZEFF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-François BERDAH, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ste Marguerite - Hyères</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marlon SILVA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse - Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane SUPIOT, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO-Centre René Gauducheau - St Herblain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loïc MOUREY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Régaud - Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier ARTIGNAN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHP Saint Grégoire - St Grégoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aude FLECHON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard - Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia BURBAN-PROVOST, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine de radiologie - St Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane DROUPY, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Carémeau - Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Christophe EYMARD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jean Godinot - Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier MURACCIOLE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Timone - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwenaëlle GRAVIS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe RONCHIN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Azuréen de Cancérologie - Mougins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe BEUZEBOC, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe HENNEQUIN, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Louis - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank PRIOU, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée - La Roche sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc FERRERO, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne - Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali HASBINI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur - Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte LAGUERRE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis - Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie ABADIE-LACOURTOISIE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO-Paul Papin - Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol ALLIOT, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Alpes Leman - Contamine sur Arve</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdennacer GHOUL, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SERA - Contamine sur Arve</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry WACHTER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR La source - Orléans</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc LANDRY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopitaux du Leman - Thonon les Bains</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy De LAROCHE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie  Lucien Neuwirth - St Priest en Jarez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne MARTIN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges-François LECLERC - Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine THIERY-VUILLEMIN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU JEAN MINJOZ - Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre CLAVERE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges - Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre De La TAILLE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor - Créteil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian PFISTTER, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rouen - Rouen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beata JUZYNA</last_name>
    <email>b-juzyna@unicancer.fr</email>
  </overall_contact>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 30, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic hormone-naive</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>abiraterone acetate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
